Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Please note: We are reviewing Western blot images included in the antibody testing data in our catalog, including those provided by third parties. Unless expressly labeled or annotated as “raw-unedited”, Western blot images included in the antibody testing data in our catalog may have been edited, optimized or otherwise adjusted for presentation.
Reconstitute at 0.5 mg/mL in sterile PBS.
CEACAM2 (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 2) is a gene that encodes a protein belonging to the carcinoembryonic antigen (CEA) family, which is part of the immunoglobulin superfamily. CEACAM2 is involved in various cellular processes, including cell adhesion, intracellular signaling, and immune responses. It is expressed in several tissues, including the brain, liver, and epithelial cells of the gastrointestinal tract. CEACAM2 plays a role in maintaining tissue architecture and integrity by mediating cell-cell adhesion. It also participates in immune regulation by interacting with other cell surface molecules to modulate the activity of immune cells, such as macrophages and natural killer (NK) cells. Dysregulation or altered expression of CEACAM2 has been associated with various diseases, including cancer, where it can influence tumor progression and metastasis, and metabolic disorders, such as obesity and type 2 diabetes. Understanding the functions and mechanisms of CEACAM2 is crucial for developing therapeutic strategies aimed at targeting its role in disease processes. Research into CEACAM2 offers insights into its potential as a biomarker for disease diagnosis and prognosis, as well as a target for novel treatments in oncology and immunotherapy.
仅用于科研。不用于诊断过程。未经明确授权不得转售。